Aquestive Therapeutics, Inc. 8-K

What Happened

• Aquestive Therapeutics, Inc. (AQST) announced in an 8‑K filed February 2, 2026 that the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) dated January 30, 2026 for the New Drug Application for Anaphylm™ (dibutepinephrine) Sublingual Film. The therapy is intended to treat Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or more (about 66 pounds).
• The company reported the deficiencies cited by the FDA were limited to packaging and administration. Aquestive said it believes these issues can be rapidly resolved and expects to resubmit the NDA as early as the third quarter of 2026. The filing also noted ongoing global regulatory engagement and plans to seek approval in Canada and Europe in 2026.

Key Details

• CRL issued by FDA: January 30, 2026; 8‑K filed: February 2, 2026.
• Indication and population: Anaphylm for Type I allergic reactions/anaphylaxis in patients ≥30 kg (~66 lb).
• Deficiencies limited to packaging and administration; company expects to resubmit potentially in Q3 2026.
• Global strategy: regulatory engagement initiated in Canada, Europe and the UK in 2025; plans to pursue regulatory approvals in Canada and Europe in 2026.

Why It Matters

• The CRL delays potential U.S. approval and any related commercial launch or U.S. revenue until Aquestive addresses the FDA’s packaging/administration deficiencies and successfully resubmits.
• Because the CRL did not cite safety or efficacy issues, the company’s statement suggests a clearer path to approval once those technical issues are resolved — a key point for investors tracking regulatory risk.
• Investors should watch for updates on the company’s resubmission timeline, responses to the CRL, and progress on regulatory filings in Canada and Europe, which could affect the company’s near‑term value drivers.